Icosavax Quarterly Income Statements Chart
Quarterly
|
Annual
Icosavax Quarterly Income Statements Table
Quarterly
|
Annual
| Unit: USD | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|
| grant revenue | 582,000 | 2,070,000 | 1,827,000 | 1,904,000 | ||||||
| operating expenses: | ||||||||||
| research and development | 16,668,000 | 19,826,000 | 17,357,000 | 16,193,000 | 15,484,000 | 15,820,000 | 17,913,000 | 14,063,000 | 10,883,000 | 8,277,000 |
| general and administrative | 8,607,000 | 9,129,000 | 9,165,000 | 8,938,000 | 7,659,000 | 7,311,000 | 6,322,000 | 6,218,000 | 25,357,000 | 2,221,000 |
| total operating expenses | 25,275,000 | 28,955,000 | 26,522,000 | 25,131,000 | 23,143,000 | 23,131,000 | 24,235,000 | 20,281,000 | 36,240,000 | 10,498,000 |
| income from operations | -25,275,000 | -28,955,000 | -26,522,000 | -25,131,000 | -23,143,000 | -23,131,000 | -23,653,000 | -18,211,000 | -34,413,000 | -8,594,000 |
| yoy | 9.21% | 25.18% | 12.13% | 38.00% | -32.75% | 169.15% | ||||
| qoq | -12.71% | 9.17% | 5.53% | 8.59% | 0.05% | -2.21% | 29.88% | -47.08% | 300.43% | |
| operating margin % | ||||||||||
| other income: | ||||||||||
| interest and other income | 3,234,000 | 2,458,000 | 1,961,000 | 29,000 | 27,000 | 42,000 | ||||
| total other income | 3,234,000 | 2,458,000 | 1,961,000 | 1,518,000 | 1,167,000 | 495,000 | 120,000 | 29,000 | 27,000 | 42,000 |
| net income | -22,041,000 | -26,497,000 | -24,561,000 | -23,613,000 | -21,976,000 | -22,636,000 | ||||
| yoy | 0.30% | 17.06% | ||||||||
| qoq | -16.82% | 7.88% | 4.01% | 7.45% | -2.92% | |||||
| net income margin % | ||||||||||
| other comprehensive income: | ||||||||||
| unrealized gains on available-for-sale debt securities | 18,000 | -3,000 | 340,000 | |||||||
| comprehensive loss | -22,023,000 | -26,500,000 | -24,221,000 | -23,407,000 | -22,310,000 | -22,911,000 | ||||
| net income per share | -0.44 | -0.59 | -0.6 | -0.59 | -0.55 | -0.57 | -0.6 | 0.77 | -1.3 | -2.86 |
| weighted-average common shares outstanding, basic and diluted | 50,030,759 | 44,770,820 | 41,264,508 | 39,725,131 | 39,748,984 | 39,594,028 | 39,401,805 | 17,965,894 | 26,494,914 | 2,985,183 |
| change in fair value of embedded derivative liability | ||||||||||
| loss on extinguishment of convertible promissory note | ||||||||||
| interest and other | 1,518,000 | 1,167,000 | 495,000 | 120,000 | ||||||
| comprehensive loss: | ||||||||||
| unrealized losses on available-for-sale debt securities | 206,000 | -334,000 | -275,000 | |||||||
| net income and comprehensive loss | -23,533,000 | -18,182,000 | -34,386,000 | -8,552,000 |
We provide you with 20 years income statements for Icosavax stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Icosavax stock. Explore the full financial landscape of Icosavax stock with our expertly curated income statements.
The information provided in this report about Icosavax stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.